Exelixis | EXEL - Operating Profit


Exelixis reported $235.91M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
Agios Pharmaceuticals USD -121.58M 4.71M Dec/2025
Akebia Therapeutics USD 13.51M 27.82M Mar/2025
Amgen USD 3.96B 464M Dec/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
Bayer EUR -543M 556M Sep/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Cytokinetics USD -166.76M 55.25M Sep/2025
Eisai JPY 20.03B 6.36B Dec/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Esperion Therapeutics USD -16.03M 18.6M Sep/2024
Exelixis USD 235.91M 20.45M Dec/2025
Genmab DKK 360M 172M Jun/2025
Glaxosmithkline GBP 3.76B 1.32B Sep/2025
Incyte USD 383.88M 47.43M Dec/2025
Ionis Pharmaceuticals USD -160.18M 300.02M Sep/2025
MacroGenics USD 18.64M 55.4M Sep/2025
Merck USD 6.24B 318M Dec/2025
Moderna USD -857M 597M Dec/2025
Nektar Therapeutics USD -34.34M 15.43M Sep/2024
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Novartis USD 4.5B 363M Sep/2025
Pfizer USD 4.65B 3.99B Dec/2025
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Sanofi EUR 1.5B 2.29B Dec/2025
Takeda JPY 168.82B 479.89B Dec/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Xencor USD -47.52M 14.35M Sep/2025